Brief: Finch Therapeutics Provides An Update On Its Phase 3 Trial Of CP101 In Recurrent C. Difficile Infection
01/03/2022 22:08
March 1 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS PROVIDES AN UPDATE ON ITS PHASE 3 TRIAL
OF
CP101 IN RECURRENT C. DIFFICILE INFECTION
* FINCH THERAPEUTICS GROUP INC - PAUSED ENROLLMENT IN
PRISM4, ITS
PHASE 3 CLINICAL TRIAL OF CP101 IN RECURRENT C. DIFFICILE
INFECTION
* FINCH THERAPEUTICS GROUP INC - PAUSED ENROLLMENT IN
PRISM4
FOLLOWING RECEIPT OF A CLINICAL HOLD LETTER FROM U.S. FDA ON
FEBRUARY 24, 2022
* FINCH THERAPEUTICS GROUP - CLINICAL HOLD LETTER FROM FDA
REQUESTING ADDITIONAL INFORMATION ABOUT FINCH'S SARS-COV-2 DONOR
SCREENING PROTOCOLS
* FINCH THERAPEUTICS GROUP INC - IN LETTER, FDA REQUESTED
ADDITIONAL DETAIL ON HOW SAMPLES ARE SHIPPED TO VENDOR
PERFORMING SARS-COV-2 TESTING
* FINCH THERAPEUTICS GROUP INC - IN LETTER, FDA REQUESTED
ADDITIONAL DETAIL ON HOW INCONCLUSIVE SARS-COV-2 TEST RESULTS
WILL BE HANDLED
Source text for Eikon: ID:nGNX3yRw2S
Further company coverage: FNCH.O
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp